According to the in vitro results of Czerwińska and Lankoff, 223Ra-labeled prostate-specific membrane antigen (PSMA)-targeting NaA nanozeolites decorated with anti-PSMA monoclonal antibody D2B (223RaA-silane-PEG-D2B) could be potential future candidates for the targeted radio-treatment of PSMA receptor-positive prostate cancer (PCa) patients [56,102]. This evidence concerns the gene FOLH1 and prostate cancer.